Soligenix, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Soligenix is a development-stage biopharmaceutical company with Specialized BioTherapeutics and Public Health Solutions segments. Revenue primarily comes from government grants and contracts; the company reported no product sales.
Financial results
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Revenue | $130,440 | $166,140 | $594,547 | $582,843 |
| Gross profit (margin) | $19,999 (15%) | $36,700 (22%) | $74,045 (12%) | $167,886 (29%) |
| Operating expenses | $1,799,055 | $3,117,944 | $5,634,114 | $10,836,812 |
| Net loss | $1,662,702 | $3,309,003 | $4,320,835 | $10,044,784 |
| Net loss per share | $0.16 | $1.15 | $0.63 | $3.50 |
- Q3 operating expenses fell 42%; nine-month expenses fell 48%. Management attributed the reductions mainly to lower HyBryte NDA-related manufacturing and regulatory costs and reduced legal and consulting costs after the Emergent arbitration.
- Nine-month operating cash use was $6.78 million, versus $9.02 million in 2022. Cash and cash equivalents were $10.30 million at September 30, down from $13.36 million at year-end 2022.
- Working capital was $5.45 million, compared with a $2.66 million deficit at year-end 2022. Total assets were $11.30 million and total liabilities $7.08 million.
- At September 30, convertible debt had $3.0 million principal and a $2.92 million fair-value carrying amount; $1.5 million was classified current and $1.42 million non-current. The debt is secured by substantially all assets other than intellectual property. The amended schedule, assuming no conversion, calls for $2.25 million principal repayment in 2024 and $750,000 in 2025.
Material changes and financing
- Net loss decreased 50% in Q3 and 57% for the first nine months year over year. Nine-month revenue rose 2%, but gross profit fell 56%, reflecting lower-margin grant revenue and the absence of higher-margin licensing revenue recorded in 2022.
- In April, Soligenix amended its Pontifax loan: repaid $5 million of principal, reduced remaining principal to $3 million, extended the interest-only period through June 30, 2024, reduced quarterly principal payments to $750,000, and removed the minimum-cash covenant. The amendment produced a $394,000 extinguishment loss; fair-value changes generated $388,000 of other income for the nine months.
- May financing generated approximately $8.5 million gross proceeds from common shares and warrants; ATM sales generated $3.09 million gross proceeds during the first nine months. Common warrants to purchase up to 6,538,500 shares at $1.50 were outstanding at quarter-end. Common shares outstanding were 10,378,238 as of November 6, 2023. Share and per-share data reflect the February 2023 one-for-fifteen reverse split.
Outlook, risks, and unusual items
- Management stated that available cash, expected grant and contract proceeds, and its operating budget should fund working capital and capital expenditures for at least 12 months from issuance of the financial statements. The company nevertheless expects continued losses and depends on controlling R&D spending, grants, partnerships, and/or additional financing. Approximately $1.0 million of active grant funding remained available at quarter-end, subject to agency continuation.
- Management estimated R&D spending of approximately $4.8 million over the next 12 months before reimbursements, including $4.7 million for Specialized BioTherapeutics; expected reimbursements of approximately $0.5 million were primarily for Public Health Solutions.
- HyBryte: The FDA refused to file the December 2022 NDA and, after an April 2023 Type A meeting, required positive results from a second Phase 3 pivotal study. Protocol discussions were ongoing; the company was assessing feasibility and exploring potential European approval based on the completed FLASH study. No U.S. approval timeline is established in the filing.
- Other programs: SGX302’s Phase 2a psoriasis study was expanded after a biological effect in its first five subjects. A second Phase 3 study for SGX942 would be required for UK marketing authorization; continued development depends on identifying a partner. Several other programs depend on government or other funding.
- Nasdaq: Soligenix regained shareholders’ equity compliance, but received a new minimum-bid-price deficiency notice in June 2023. It had until December 20, 2023 to regain compliance, with a potential additional compliance period subject to conditions. A one-year Panel Monitor also applied.
- Legal and other items: The Delaware Court of Chancery ruled for Emergent in July 2023, confirming an arbitration decision that awarded Soligenix no monetary damages despite finding contract breaches. A $120,771 CARES Act employee-retention-credit refund received after quarter-end was recorded as Q3 and nine-month other income. The company paid $50,000 cash and issued shares valued at $50,000 for an option to acquire Silk Road assets; the option expired in August after due diligence, and a director had an ownership interest in Silk Road.
- Key risks include clinical and regulatory setbacks, reliance on grants and external financing, potential dilution, Nasdaq listing compliance, and uncertainty in partnerships and commercialization. Management reported disclosure controls were effective as of September 30, 2023.
Important facts for investors to verify
- Progress and final terms of FDA discussions on the required second HyBryte Phase 3 study, including its cost, funding, and timing.
- Cash burn relative to the stated 12-month runway, grant availability, and access to additional financing; ATM capacity was limited by Form S-3 public-float restrictions as of November 6, 2023.
- Debt repayment terms, conversion provisions, and potential dilution from outstanding warrants and other securities.
- Nasdaq bid-price compliance status and any consequences of the December 20, 2023 deadline.
- Funding or partnership milestones for SGX942 and other programs, and any additional costs or recoveries related to the Emergent dispute.